Spotlight On... FDA underestimated fetal deaths linked to Bayer's Essure contraceptive: Analyst; Merck nabs rights to Daiichi's Lixiana in 13 European countries; Perrigo misses quarterly profit estimates; and more...

Essure--Screenshot courtesy of Bayer

It's more bad news for Bayer in the safety saga over its contraceptive implant, Essure. The FDA in the past has cited 5 fetal deaths linked to the device. But now one analyst is pegging this number much higher. After scouring the agency's side effects reporting database, Madris Tomes, founder and chief executive of data analysis company Device Events, found 303 fetal deaths associated with the product. The news comes as the FDA decides whether to beef up its oversight of Essure after receiving thousands of reports of serious problems from women who used the implant. More from FierceMedicalDevices

@FiercePharma: India aims to detail new policies next month to boost bulk drug output. FiercePharmaAsia report | Follow @FiercePharma

@EricPFierce: New York gives $200M for Athenix to build Buffalo plant. Company pledges 900 jobs over 10 years. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Merck's new hep C contender Zepatier faces a long runway, but 2017 could bring takeoff. Article | Follow @CarlyHFierce

> Daiichi Sankyo has granted Merck ($MRK) exclusive rights to market its next-gen anticoagulant, Lixiana, in 13 European countries. More

> Perrigo ($PRGO) fell short of profit estimates for the first time in 5 quarters for the period ended Dec. 31; it attributed the miss to higher costs and disappointing performance in its branded consumer healthcare unit. More

> Indian drugmaker Cipla has sealed its $550 million acquisition of U.S. generics makers InvaGen Pharmaceuticals and Exelan Pharmaceuticals. More

> Diplomat Pharmacy has announced that it is now filling prescriptions for Merck's new hep C combo treatment Zepatier. More

> New research suggests that college students looking for an academic edge may explain a surge in the misuse of ADHD med Adderall. More

> Pakistan's Ministry of National Health Services is teaming up with Novo Nordisk Pakistan to improve awareness and education on diabetes. More

> Johnson & Johnson ($JNJ) is calling for new ideas on how to reduce HIV infections in sub-Saharan Africa. Release

Medical Device News

@FierceMedDev: ICYMI yesterday: Virtual reality startup reels in $100M for rehabilitation device. Article | Follow @FierceMedDev

@VarunSaxena2: Direct Flow Medical throws its hat in the transcatheter mitral valve arena ring. Article | Follow @VarunSaxena2

@EmilyWFierce: In Dx Digest: Sysmex and Eisai focus on dementia tests and Apogenix gets €3 million for cancer companion Dx. Report | Follow @EmilyWFierce

> Novartis buys minimally invasive glaucoma surgery player to boost its Alcon eyecare unit. Story

> FDA downplayed fetal deaths linked to Bayer's Essure contraceptive: Analyst. Report

> IBM Watson Health to buy Truven for $2.6B in fourth health data deal. Article

Biotech News

@FierceBiotech: Academic medical centers get an F for trial transparency. Article | Follow @FierceBiotech

@JohnCFierce: Third Rock launches Pliant, gambling $45M on a next-gen approach to fibrosis. Report | Follow @JohnCFierce

@DamianFierce: de Saussure Capital. More | Follow @DamianFierce

> Third Rock launches Pliant, gambling $45M on a next-gen approach to fibrosis. News

> Zafgen touts its obesity drug as safety threat continues to plague outcomes. Story

> Celgene opts in as bluebird starts first CAR-T clinical trial. Article

CRO News

> Former GSK staffers help Parexel expand genomics offering. Story

> AMRI scores a revenue jump after a spate of deals. Article

> INC cozies up to trial sites in hopes of improving R&D results. Report

> CRO Analytics raises cash to advance its cloud-based data service. News

Pharma Manufacturing News

> Cipla secures first U.S. manufacturing plant. News

> AMRI's revenues soar 45% as refocus on contract manufacturing pays off. More

> GSK targets Indian plant for $73M in upgrades. Report

> Compounder recalls superpotent morphine tied to adverse reactions in babies. Story

> Biotech Alnylam commits $100M to plant for its RNAi therapy. Article

Pharma Asia News

> Athenex details $225M China-New York drug manufacturing play. Item

> S. Africa hauls up India's Ranbaxy over bacteria found in folic acid tablets. Story

> Lightstone Ventures joins with Singapore for $50M fund. News

> Sosei revs up work with Heptares candidates, seeks partners. Report

> India aims to detail new policies next month to boost bulk drug output. Article

And Finally... Employee wellness firms and insurers are working with companies to mine data about the prescription drugs workers use to predict which of them may get sick. More

Suggested Articles

Mobile has become universal, accessible, and multi-generational. It’s time for life science brands to revolutionize how they’re telling their story.

Former Retrophin CEO was hoping for a SCOTUS hail mary to escape his seven-year fraud sentences Turns out the court was interest in hearing his plea.

A new investigation shines light on how Purdue pushed back on negative coverage of opioids, placed opioid-friendly experts in think tanks and more.